(Fighting against New Coronary Pneumonia) National Medical Insurance Administration of China: Temporary inclusion of new coronavirus antigen detection reagents in basic medical insurance
China News Service, Beijing, March 21. China's National Medical Security Administration issued a notice on the 21st to effectively do a good job in the current epidemic prevention and control medical security work, requiring the new coronavirus antigen detection reagent and corresponding testing items to be temporarily included in the province's basic medical insurance according to procedures. Directory of medical services.
The "Notice" pointed out that all provincial medical security departments should comprehensively consider the needs of epidemic prevention and control in accordance with the "New Coronavirus Pneumonia Diagnosis and Treatment Plan (Trial Version 9)" and the "New Coronavirus Pneumonia Prevention and Control Plan (Trial Version 9)" . The payment capacity of the medical insurance fund in the region shall be adjusted and optimized in a timely manner in accordance with the principles of scientific precision, activeness and stability, and risk controllability.
The "Notice" requires that the new coronavirus antigen detection reagents and corresponding detection items be temporarily included in the province's basic medical insurance medical service project catalog according to the procedures.
The relevant expenses incurred by the insured in the designated primary medical institutions shall be paid in accordance with the current regulations of the overall planning area, and the expenses of purchasing testing reagents at the designated retail pharmacies can be paid using personal accounts.
All provincial medical security departments, with reference to relevant documents, continue to standardize and optimize the price policy for public medical institutions to provide COVID-19 antigen testing services.
Centralized pharmaceutical procurement agencies in various regions should do a good job in the online purchase of novel coronavirus antigen detection reagents, actively promote online purchases, and rely on the national unified medical insurance information platform for information sharing.
At the same time, it will strengthen the calculation and monitoring, and coordinate the promotion of price, procurement, payment and information system transformation.
The "Notice" also pointed out that it is necessary to adjust the new crown treatment drugs included in the medical insurance payment in a timely manner.
For the newly added drugs in the diagnosis and treatment plan (trial version 9), the provincial medical security departments refer to relevant requirements and temporarily include them in the payment scope of the provincial medical insurance fund; For the medicines in the catalog, all provincial medical security departments shall stop medical insurance payment from the date of the release of the diagnosis and treatment plan (the ninth version for trial implementation).
In addition, the "Notice" requires all provincial medical security departments to do a good job in the work of adding new drugs to the Internet. For drugs that have not yet been linked to the Internet, medical institutions are allowed to purchase emergency use offline first.
The newly added naimatevir tablets/ritonavir tablets of the diagnosis and treatment plan (trial version 9) shall be purchased by the medical institution according to the price agreed between the enterprise and the relevant departments, and the medical insurance department shall pay according to the regulations.
(over)